Zymeworks Inc reports results for the quarter ended December 31 - Earnings Summary

• Zymeworks Inc ZYME.OQ reported a quarterly adjusted loss of 55 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -31 cents. The mean expectation of twelve analysts for the quarter was for a loss of 42 cents per share. Wall Street expected results to range from -72 cents to 3 cents per share.

• Revenue fell 91.9% to $2.52 million from a year ago; analysts expected $13.58 million.

• Zymeworks Inc's reported EPS for the quarter was a loss of 55 cents​.

• The company reported a quarterly loss of $41.21 million.

• Zymeworks Inc shares had fallen by 11.5% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 6.1% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Zymeworks Inc is $34.00, about 31.5% above its last closing price of $23.29

This summary was machine generated from LSEG data March 2 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)